Purpose Cetuximab or panitumumab are effective in 10% to 20% unselected metastatic
colorectal cancer (CRC) patients. KRAS mutations account for approximately 30% to 40 …

Approximately 45% of metastatic colorectal cancer (mCRC) patients with wild-type KRAS
exon 2 are resistant to cetuximab treatment. We set out to identify additional genetic markers …

Purpose: While mutations in BRAF in metastatic colorectal cancer (mCRC) most commonly
occur at the V600 amino acid, with the advent of next-generation sequencing, non-V600 …

PURPOSE BRAF V600E mutations are rarely associated with objective responses to the
BRAF inhibitor vemurafenib in patients with metastatic colorectal cancer (CRC). Blockade of …

520 Background: BRAF V600 mutations are associated with rare objective responses to the
mutated BRAF inhibitor vemurafenib in patients with mCRC. Blockade of BRAFV600 by …

Purpose: BRAF-mutant metastatic colorectal cancer (mCRC) forms an aggressive subset of
colorectal cancer with minimal response to selective RAF inhibitors. Preclinical data show …

Background Patients with metastatic colorectal cancer with the BRAF V600E mutation have
a poor prognosis, with a median overall survival of 4 to 6 months after failure of initial …

BACKGROUND: The CRYSTAL and OPUS randomised clinical trials demonstrated that
adding cetuximab to first-line chemotherapy in patients with KRAS wild-type metastatic …

Background Following the discovery that mutant KRAS is associated with resistance to anti-
epidermal growth factor receptor (EGFR) antibodies, the tumours of patients with metastatic …

Introduction: BRAF driver mutations are found in up to 15% of patients with colorectal cancer
(CRC) and lead to constitutive activation of BRAF kinase and sustained RAS/RAF/MEK/ERK …